drugset / Trial / NCT07615270
A Pilot Study of Anselamimab in Patients With AL Amyloidoma and Measurable Tissue Involvement
NaSingle-groupOpen-labelTreatment
Summary
This is an exploratory study to assess the binding of CAEL-101/anselamimab to amyloid in vivo, recruitment of inflammatory cells and reduction of the amyloid mass.
Timeline
- Start
- 2026-07
- Primary completion
- 2028-07
- Completion
- 2028-07
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Anselamimab | Protein / enzyme biologic | 1000 mg/m2 | Intravenous |